After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA has re-opened the door for GLP-1 compounders.
After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA has re-opened the door for GLP-1 compounders.
© 2023 LBNN - All rights reserved.